Reversible Cerebral Vasoconstriction Syndrome in the Setting of COVID-19 and Pleomorphic Sarcoma: A Case Report.


Journal

The neurologist
ISSN: 2331-2637
Titre abrégé: Neurologist
Pays: United States
ID NLM: 9503763

Informations de publication

Date de publication:
01 May 2022
Historique:
pubmed: 3 12 2021
medline: 10 5 2022
entrez: 2 12 2021
Statut: epublish

Résumé

Reversible cerebral vasonstriction syndrome (RCVS) is an increasingly recognized clinical and radiologic syndrome. However, it has been rarely reported in the setting of the novel coronavirus disease-2019 (COVID-19) infection or sarcomatous tumors. RCVS might be the initial manifestations of COVID-19 infection or noncatecholamine producing masses including sarcoma. A 44-year-old male who developed COVID-19-related symptoms followed by rapid onset of severe headaches in the setting of persistently elevated blood pressure (BP). Brain imaging showed multifocal arterial narrowing in the anterior and posterior circulation consistent with RCVS. Serial imaging demonstrated resolution of the arterial narrowing after BP control was achieved with improvement in the patient's headaches. Further investigation for secondary causes of the patient's elevated BP revealed a right renal mass, and the patient underwent right nephrectomy, and the biopsy results confirmed the diagnosis of pleomorphic sarcoma. Our case suggests a possible association between severe acute respiratory syndrome coronavirus 2 with development of RCVS, but further studies are needed to validate this observation, establish a causal relationship and define a pathophysiological mechanism. Considering tumors other than catecholamine-producing masses as a potential risk factor for developing RCVS might lead to earlier detection and treatment of any underlying malignancy in patients whom the main and sole presentation could be RCVS.

Identifiants

pubmed: 34855668
doi: 10.1097/NRL.0000000000000387
pii: 00127893-202205000-00009
pmc: PMC9066509
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

135-138

Informations de copyright

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol. 2012;11:906–917.
Miller TR, Shivashankar R, Mossa-Basha M, et al. Reversible cerebral vasoconstriction syndrome, part 1: epidemiology, pathogenesis, and clinical course. Am J Neuroradiol. 2015;36:1392–1399.
Sattar A, Manousakis G, Jensen MB. Systematic review of reversible cerebral vasoconstriction syndrome. Expert Rev Cardiovasc Ther. 2010;8:1417–1421.
Josephson SA, Kamel H. Neurology and COVID-19. JAMA. 2020;324:1139–1140.
Dakay K, Kaur G, Gulko E, et al. Reversible cerebral vasoconstriction syndrome and dissection in the setting of COVID-19 infection. J Stroke Cerebrovasc Dis. 2020;29:105011. Available at: https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105011 .
doi: 10.1016/j.jstrokecerebrovasdis.2020.105011
Anderson NE, Chung K, Willoughby E, et al. Neurological manifestations of phaeochromocytomas and secretory paragangliomas: a reappraisal. J Neurol Neurosurg Psychiatry. 2013;84:452–457.
Pantoja-Ruiz C, Ricaurte-Fajardo A, Ocampo-Navia MI, et al. Reversible cerebral vasoconstriction syndrome associated with a suprarenal mass. Prague Med Rep. 2020;121:107–113.
Calabrese LH, Dodick DW, Schwedt TJ, et al. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med. 2007;146:34–44.
Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020;158:1518–1519.
Saavedra JM. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol Neurobiol. 2005;25:485–512.
Divani AA, Andalib S, Di Napoli M, et al. Coronavirus disease 2019 and stroke: clinical manifestations and pathophysiological insights. J Stroke Cerebrovasc Dis. 2020;29:104941. Available at: https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104941 .
doi: 10.1016/j.jstrokecerebrovasdis.2020.104941
Madhok J, Kloosterboer A, Venkatasubramanian C, et al. Catecholamine-induced cerebral vasospasm and multifocal infarctions in pheochromocytoma. Endocrinol Diabetes Metab Case Rep. 2020. Available at: https://doi.org/10.1530/EDM-20-0078 .
doi: 10.1530/EDM-20-0078
Rocha EA, Topcuoglu MA, Silva GS, et al. RCVS2 score and diagnostic approach for reversible cerebral vasoconstriction syndrome. Neurology. 2019;92:e639–e647.
Topcuoglu MA, Singhal AB. Hemorrhagic reversible cerebral vasoconstriction syndrome: features and mechanisms. Stroke. 2016;47:1742–1747.

Auteurs

Ehab Harahsheh (E)

Departments of Neurology.

David Gritsch (D)

Departments of Neurology.

Amir Mbonde (A)

Departments of Neurology.

Michael Apolinario (M)

Internal medicine.

Joseph M Hoxworth (JM)

Radiology, Mayo Clinic College of Medicine and Science, Scottsdale, AZ.

Bart M Demaerschalk (BM)

Departments of Neurology.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH